Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2381-2389

  Schirrmeister, Holger ^a   Guhlmann, Albrecht ^a   Kotzerke, Jörg ^a   Santjohanser, Claudia ^a   Kühn, Thorsten ^a   Kreienberg, Rolf ^a   Messer, Peter ^a   Nüssle, Karin ^a   Elsner, Klaus ^a   Glatting, Gerhard ^a   Träger, Harald ^a   Neumaier, Bernd ^a   Diederichs, Christoph ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; FLUORINE 18; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 0032784695     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2381     Document Type: Article

References (41)

1. Perez DJ, Powles TJ, Milan J, et al: Detection of breast carcinoma metastases in bone: Relative merits of x-rays and skeletal scintigraphy. Lancet 2:613-616, 1983
2. Rossing N, Munck O, Nielsen SP, et al: What do early bone scans tell about breast cancer patients? Eur J Cancer Clin Oncol 18:629-636, 1982
3. Kunkler IH, Merrick MV: The value of non-staging skeletal scintigraphy in breast cancer. Clin Radiol 37:561-562, 1986
4. Alexieva-Figusch J, van Putten WLV, Blankenstein MA, et al: The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61:758-768, 1988
5. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
6. Kamby C, Bruun Rasmussen B, Kristensen B: Prognostic indicators of metastatic bone disease in human breast cancer. Cancer 68:2045-2050, 1991
7. Houston SJ, Rubens RD: The systemic treatment of bone metastases. Clin Orthop 312:95-104, 1995
8. Reske SN, Karstens JH, Gloekner W, et al: Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet 11:299-301, 1989
9. Blair JSG: Does early detection of bone metastases by scanning improve prognosis in breast cancer? Clin Oncol 1:185-190, 1975
10. Merrick MV: Bone scintigraphy: an update. Clin Radiol 40:231-232, 1989
11. Recommended breast cancer surveillance guidelines. J Clin Oncol 15:2149-2156, 1997
12. Simon M, Stano M, Hussein M, et al: An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer. Breast Cancer Res Treat 37:39-47, 1996
13. Citrin DL, Bessent RG, Greig WM: A comparison of the sensitivity and accuracy of the Tc-99m-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases. Clin Radiol 28:107-117, 1977
14. Avrami E, Tadmor R, Dally O, et al: Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans. J Comput Assist Tomogr 13:598-602, 1989
15. Brown B, Laorr A, Greenspan A, et al: Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med 19:194-196, 1994
16. Thrupkaew AK, Henkin RE, Quinn JL: False negative bone scans in disseminated metastatic disease. Radiology 113:383-386, 1974
17. Haubold-Reuter, Duwell S, Schilcher Marincek B, et al: The value of bone scintigraphy, bone marrow scintigraphy and fast spin magnetic resonance imaging in staging of patients with malignant solid tumors: A prospective study. Eur J Nucl Med 20:1063-1069, 1993
18. Franks JA, Ling A, Patronas NJ, et al: Detection of malignant bone tumors: MR imaging vs scintigraphy. Am J Roentgenol 155:1043-1048, 1990
19. Krishnamurthy GT, Thomas PB, Tubis M, et al: Comparison of 99m-Tc polyphosphate and F-18: I. Kinetics. J Nucl Med 15:832-836, 1974
20. Hawkins RA, Choi Y, Huang SC, et al: Evaluation of skeletal kinetics of fluorine 18-fluoride ion with PET. J Nucl Med 33:633-642, 1992
21. Hoh CK, Hawkins RA, Dahlbom M, et al: Whole body skeletal imaging with [F-18] fluoride ion and PET. J Comput Assist Tomogr 17:34-41, 1992
22. Schieper C, Nuyts J, Bormans G, et al: Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 38:1970-1976, 1997
23. Silberstein EB, Saenger EL, Tofe AJ, et al: Imaging of bone metastases with 99m Tc-Sn-EHDP (diphosphonate), 18 F, and skeletal radiograph: A comparison of sensitivity. Radiology 107:551-555, 1973
24. Weber DA, Keyes JW, Landman S, et al: Comparison of Tc99m polyphosphate and F18 for bone imaging. Am J Roentgenol Radium Ther Nucl Med 121:184-190, 1974
25. Schirrmeister H, Rentschler M, Kotzerke J, et al: Skeletal imaging with 18FNa-PET and comparison with planar scintigraphy. Fortschr Rontgenstr 168:451-456, 1998
26. Donohoe KJ, Henkin RE, Royal HD, et al: Procedure guideline for bone scintigraphy: 1.0. Society of Nuclear Medicine. J Nucl Med 37:1903-1906, 1996
27. Schmidlin P: Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 21:930-936, 1994
28. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843, 1983
29. Kosuda S, Tatsumi K, Yokoyama H, et al: Does bone SPECT actually have a lower sensitivity than MRI? J Nucl Med 37:975-978, 1996
30. Galasko CSB: Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop 312:64-73, 1995
31. Yamashita K, Koyama H, Inaji H: Prognostic significance of bone metastases from breast cancer. Clin Orthop 312:89-94, 1995
32. Gibril F, Doppman JL, Reynolds JC, et al: Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 16:1040-1053, 1998
33. Schutte HE: The influence of bone pain on the results of bone scans. Cancer 44:2039-2043, 1979
34. Noguchi S, Miyauchi K, Nishizawa Y, et al: Results of surgical treatment for sternal metastases in breast cancer. Cancer 60:2524-2531, 1987
35. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
36. Ayash LJ, Wheeler C, Reich E, et al: Double dose-intensified chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer. J Clin Oncol 12:37-44, 1994
37. Bezwoda WR, Seymour L, Dansey RD: High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
38. van Holten-Verzantvoort AT, Bijovoet OL, Cleton FJ, et al: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (ADP) treatment. Lancet 31:983-985, 1987
39. Sasaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995
40. Diel IJ, Solomayer EF, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998
41. Fickinger FW, Sanal SM: Bone marrow MRI: Techniques and accuracy for detecting breast cancer metastases. Magn Reson Imaging 12:829-835, 1994